# ORBIMED ADVISORS LLC

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1055951. Source: https://holderbook.com/funds/1055951-orbimed-advisors-llc/

- Reported value: $5.4B
- Positions: 123
- Weight of the ten largest: 42.1%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| EDGEWISE THERAPEUTICS INC | [EWTX](https://holderbook.com/stocks/EWTX/) | $630.5M | 15,518,492 | 11.7% | 22 |
| ENLIVEN THERAPEUTICS INC | [ELVN](https://holderbook.com/stocks/ELVN/) | $343.9M | 6,776,632 | 6.4% | 14 |
| ELI LILLY & CO | [LLY](https://holderbook.com/stocks/LLY/) | $309.3M | 257,900 | 5.7% | 14 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $189.3M | 3,428,736 | 3.5% | 8 |
| SINOVAC BIOTECH LTD | [SVA](https://holderbook.com/stocks/SVA/) | $184.5M | 2,718,735 | 3.4% | 17 |
| ASTRAZENECA PLC | [AZN](https://holderbook.com/stocks/AZN/) | $171.1M | 915,700 | 3.2% | 2 |
| STRUCTURE THERAPEUTICS INC | [GPCR](https://holderbook.com/stocks/GPCR/) | $118.6M | 2,209,400 | 2.2% | 9 |
| SIONNA THERAPEUTICS INC | [SION](https://holderbook.com/stocks/SION/) | $112.4M | 2,555,877 | 2.1% | 6 |
| CORVUS PHARMACEUTICALS INC | [CRVS](https://holderbook.com/stocks/CRVS/) | $107.0M | 7,165,006 | 2.0% | 31 |
| ARRIVENT BIOPHARMA INC | [AVBP](https://holderbook.com/stocks/AVBP/) | $105.2M | 3,027,328 | 1.9% | 10 |
| ABIVAX SA | [ABVX](https://holderbook.com/stocks/ABVX/) | $99.5M | 546,522 | 1.8% | 4 |
| GUARDANT HEALTH INC | [GH](https://holderbook.com/stocks/GH/) | $87.6M | 583,700 | 1.6% | 2 |
| ARGENX SE | [ARGX](https://holderbook.com/stocks/ARGX/) | $86.2M | 92,880 | 1.6% | 18 |
| MERCK & CO INC | [MRK](https://holderbook.com/stocks/MRK/) | $85.2M | 663,400 | 1.6% | 2 |
| UNIQURE NV | [QURE](https://holderbook.com/stocks/QURE/) | $83.3M | 1,807,486 | 1.5% | 4 |
| PRAXIS PRECISION MEDICINES I | [PRAX](https://holderbook.com/stocks/PRAX/) | $77.0M | 230,100 | 1.4% | 3 |
| EDWARDS LIFESCIENCES CORP | [EW](https://holderbook.com/stocks/EW/) | $75.5M | 834,900 | 1.4% | 7 |
| PRELUDE THERAPEUTICS INC | [PRLD](https://holderbook.com/stocks/PRLD/) | $73.2M | 13,724,571 | 1.4% | 24 |
| DYNE THERAPEUTICS INC | [DYN](https://holderbook.com/stocks/DYN/) | $71.9M | 3,235,684 | 1.3% | 10 |
| NATERA INC | [NTRA](https://holderbook.com/stocks/NTRA/) | $71.1M | 262,000 | 1.3% | 31 |
| UNITEDHEALTH GROUP INC | [UNH](https://holderbook.com/stocks/UNH/) | $71.1M | 161,100 | 1.3% | 1 |
| CG ONCOLOGY INC | [CGON](https://holderbook.com/stocks/CGON/) | $69.1M | 972,800 | 1.3% | 8 |
| ARS PHARMACEUTICALS INC | [SPRY](https://holderbook.com/stocks/SPRY/) | $66.4M | 8,288,510 | 1.2% | 23 |
| ASCENDIS PHARMA A/S | [ASND](https://holderbook.com/stocks/ASND/) | $65.2M | 244,456 | 1.2% | 1 |
| HUMANA INC | [HUM](https://holderbook.com/stocks/HUM/) | $65.2M | 164,100 | 1.2% | 1 |
| COGENT BIOSCIENCES INC | [COGT](https://holderbook.com/stocks/COGT/) | $65.1M | 1,681,300 | 1.2% | 3 |
| BOSTON SCIENTIFIC CORP | [BSX](https://holderbook.com/stocks/BSX/) | $63.3M | 1,483,200 | 1.2% | 31 |
| INTUITIVE SURGICAL INC | [ISRG](https://holderbook.com/stocks/ISRG/) | $62.8M | 157,900 | 1.2% | 31 |
| MINERALYS THERAPEUTICS INC | [MLYS](https://holderbook.com/stocks/MLYS/) | $56.9M | 2,110,300 | 1.1% | 5 |
| ODYSSEY THERAPEUTICS INC | [ODTX](https://holderbook.com/stocks/ODTX/) | $56.2M | 3,001,198 | 1.0% | 1 |
| XENON PHARMACEUTICALS INC | [XENE](https://holderbook.com/stocks/XENE/) | $53.9M | 892,471 | 1.0% | 31 |
| ARCUTIS BIOTHERAPEUTICS INC | [ARQT](https://holderbook.com/stocks/ARQT/) | $53.5M | 2,042,000 | 1.0% | 1 |
| BRISTOL-MYERS SQUIBB CO | [BMY](https://holderbook.com/stocks/BMY/) | $53.3M | 925,000 | 1.0% | 3 |
| Q32 BIO INC | [QTTB](https://holderbook.com/stocks/QTTB/) | $52.6M | 4,127,987 | 1.0% | 10 |
| PALVELLA THERAPEUTICS INC NE | [PVLA](https://holderbook.com/stocks/PVLA/) | $50.8M | 292,360 | 0.9% | 2 |
| STRYKER CORPORATION | [SYK](https://holderbook.com/stocks/SYK/) | $50.1M | 159,100 | 0.9% | 24 |
| CARIS LIFE SCIENCES INC | [CAI](https://holderbook.com/stocks/CAI/) | $50.0M | 2,806,811 | 0.9% | 5 |
| ELEVANCE HEALTH INC FORMERLY | [ELV](https://holderbook.com/stocks/ELV/) | $48.2M | 114,700 | 0.9% | 3 |
| SPDR SERIES TRUST | [XBI](https://holderbook.com/stocks/XBI/) | $47.5M | 0 | 0.9% | 1 |
| THERMO FISHER SCIENTIFIC INC | [TMO](https://holderbook.com/stocks/TMO/) | $45.5M | 90,700 | 0.8% | 31 |
| SHATTUCK LABS INC | [STTK](https://holderbook.com/stocks/STTK/) | $43.8M | 6,306,127 | 0.8% | 4 |
| UPSTREAM BIO INC | [UPB](https://holderbook.com/stocks/UPB/) | $39.4M | 5,693,589 | 0.7% | 7 |
| CRINETICS PHARMACEUTICALS IN | [CRNX](https://holderbook.com/stocks/CRNX/) | $37.4M | 999,000 | 0.7% | 31 |
| RHYTHM PHARMACEUTICALS INC | [RYTM](https://holderbook.com/stocks/RYTM/) | $35.9M | 322,900 | 0.7% | 12 |
| SYNDAX PHARMACEUTICALS INC | [SNDX](https://holderbook.com/stocks/SNDX/) | $33.7M | 1,542,000 | 0.6% | 2 |
| FORTE BIOSCIENCES INC | [FBRX](https://holderbook.com/stocks/FBRX/) | $33.5M | 1,577,705 | 0.6% | 7 |
| COMPASS THERAPEUTICS INC | [CMPX](https://holderbook.com/stocks/CMPX/) | $33.3M | 15,219,994 | 0.6% | 19 |
| NEKTAR THERAPEUTICS | [NKTR](https://holderbook.com/stocks/NKTR/) | $32.5M | 465,346 | 0.6% | 2 |
| KRYSTAL BIOTECH INC | [KRYS](https://holderbook.com/stocks/KRYS/) | $30.9M | 83,200 | 0.6% | 11 |
|  | - | $30.3M | 5,680,186 | 0.6% | 1 |
| AXSOME THERAPEUTICS INC | [AXSM](https://holderbook.com/stocks/AXSM/) | $28.8M | 117,578 | 0.5% | 6 |
| KINIKSA PHARMACEUTICALS INTL | [KNSA](https://holderbook.com/stocks/KNSA/) | $26.9M | 420,600 | 0.5% | 3 |
| TREVI THERAPEUTICS INC | [TRVI](https://holderbook.com/stocks/TRVI/) | $26.7M | 1,430,293 | 0.5% | 6 |
| DISC MEDICINE INC | [IRON](https://holderbook.com/stocks/IRON/) | $26.2M | 357,535 | 0.5% | 15 |
| WEST PHARMACEUTICAL SVSC INC | [WST](https://holderbook.com/stocks/WST/) | $25.3M | 70,600 | 0.5% | 1 |
| RELMADA THERAPEUTICS INC | [RLMD](https://holderbook.com/stocks/RLMD/) | $25.1M | 3,631,195 | 0.5% | 3 |
| UROGEN PHARMA LTD | [URGN](https://holderbook.com/stocks/URGN/) | $24.9M | 676,187 | 0.5% | 5 |
| SUTRO BIOPHARMA INC | [STRO](https://holderbook.com/stocks/STRO/) | $24.7M | 743,944 | 0.5% | 2 |
| SAVARA INC | [SVRA](https://holderbook.com/stocks/SVRA/) | $24.4M | 3,959,900 | 0.5% | 2 |
| NEUROPACE INC | [NPCE](https://holderbook.com/stocks/NPCE/) | $23.9M | 1,505,125 | 0.4% | 21 |
| AURA BIOSCIENCES INC | [AURA](https://holderbook.com/stocks/AURA/) | $23.7M | 3,333,333 | 0.4% | 1 |
| PROTAGONIST THERAPEUTICS INC | [PTGX](https://holderbook.com/stocks/PTGX/) | $23.5M | 42,100 | 0.4% | 3 |
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $22.6M | 70,500 | 0.4% | 3 |
| ORIC PHARMACEUTICALS INC | [ORIC](https://holderbook.com/stocks/ORIC/) | $21.8M | 2,015,000 | 0.4% | 6 |
| CYBIN INC | [HELP](https://holderbook.com/stocks/HELP/) | $21.6M | 3,271,400 | 0.4% | 3 |
| BIOCRYST PHARMACEUTICALS INC | [BCRX](https://holderbook.com/stocks/BCRX/) | $18.5M | 1,852,000 | 0.3% | 4 |
| BIOAGE LABS INC | [BIOA](https://holderbook.com/stocks/BIOA/) | $18.4M | 752,153 | 0.3% | 8 |
| LEXEO THERAPEUTICS INC | [LXEO](https://holderbook.com/stocks/LXEO/) | $18.4M | 3,947,850 | 0.3% | 3 |
| WHITEHAWK THERAPEUTICS INC | [WHWK](https://holderbook.com/stocks/WHWK/) | $18.0M | 3,934,296 | 0.3% | 6 |
| DEFINIUM THERAPEUTICS INC | [DFTX](https://holderbook.com/stocks/DFTX/) | $17.2M | 365,400 | 0.3% | 2 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $16.5M | 186,145 | 0.3% | 1 |
| CORBUS PHARMACEUTICALS HLDGS | [CRBP](https://holderbook.com/stocks/CRBP/) | $16.3M | 1,737,287 | 0.3% | 8 |
| VERA THERAPEUTICS INC | [VERA](https://holderbook.com/stocks/VERA/) | $15.9M | 369,596 | 0.3% | 3 |
| ALUMIS INC | [ALMS](https://holderbook.com/stocks/ALMS/) | $15.4M | 548,163 | 0.3% | 5 |
| EYEPOINT INC | [EYPT](https://holderbook.com/stocks/EYPT/) | $15.3M | 1,069,147 | 0.3% | 4 |
| WATERS CORP | [WAT](https://holderbook.com/stocks/WAT/) | $15.1M | 40,300 | 0.3% | 1 |
| MONOPAR THERAPEUTICS INC | [MNPR](https://holderbook.com/stocks/MNPR/) | $14.6M | 157,423 | 0.3% | 1 |
| TRAVERE THERAPEUTICS INC | [TVTX](https://holderbook.com/stocks/TVTX/) | $14.4M | 253,000 | 0.3% | 1 |
| TAYSHA GENE THERAPIES INC | [TSHA](https://holderbook.com/stocks/TSHA/) | $13.6M | 2,000,000 | 0.3% | 1 |
| BIOGEN INC | [BIIB](https://holderbook.com/stocks/BIIB/) | $13.3M | 61,600 | 0.2% | 2 |
| DIANTHUS THERAPEUTICS INC | [DNTH](https://holderbook.com/stocks/DNTH/) | $11.2M | 115,000 | 0.2% | 1 |
| SPRUCE BIOSCIENCES INC | [SPRB](https://holderbook.com/stocks/SPRB/) | $10.8M | 200,000 | 0.2% | 1 |
| LIFESTANCE HEALTH GROUP INC | [LFST](https://holderbook.com/stocks/LFST/) | $10.1M | 947,400 | 0.2% | 2 |
| ERASCA INC | [ERAS](https://holderbook.com/stocks/ERAS/) | $9.1M | 495,900 | 0.2% | 1 |
| PROTARA THERAPEUTICS INC | [TARA](https://holderbook.com/stocks/TARA/) | $8.5M | 2,220,000 | 0.2% | 1 |
| KEROS THERAPEUTICS INC | [KROS](https://holderbook.com/stocks/KROS/) | $8.1M | 759,155 | 0.2% | 25 |
| JANUX THERAPEUTICS INC | [JANX](https://holderbook.com/stocks/JANX/) | $8.1M | 524,700 | 0.1% | 21 |
| TECTONIC THERAPEUTIC INC | [TECX](https://holderbook.com/stocks/TECX/) | $7.8M | 226,600 | 0.1% | 3 |
| ADICET BIO INC | [ACET](https://holderbook.com/stocks/ACET/) | $7.3M | 844,787 | 0.1% | 3 |
| PHARVARIS N V | [PHVS](https://holderbook.com/stocks/PHVS/) | $7.1M | 205,400 | 0.1% | 3 |
| ALTO NEUROSCIENCE INC | [ANRO](https://holderbook.com/stocks/ANRO/) | $6.8M | 257,852 | 0.1% | 7 |
| ZENTALIS PHARMACEUTICALS INC | [ZNTL](https://holderbook.com/stocks/ZNTL/) | $6.7M | 1,390,576 | 0.1% | 1 |
| BRIGHT MINDS BIOSCIENCES INC | [DRUG](https://holderbook.com/stocks/DRUG/) | $6.5M | 93,000 | 0.1% | 2 |
| ALX ONCOLOGY HLDGS INC | [ALXO](https://holderbook.com/stocks/ALXO/) | $5.9M | 2,866,256 | 0.1% | 2 |
| TRAVERE THERAPEUTICS INC | - | $5.9M | 5,000,000 | 0.1% | 1 |
| XILIO THERAPEUTICS INC | [XLO](https://holderbook.com/stocks/XLO/) | $5.7M | 592,300 | 0.1% | 1 |
| BICARA THERAPEUTICS INC | [BCAX](https://holderbook.com/stocks/BCAX/) | $5.7M | 191,100 | 0.1% | 3 |
| IMAGENEBIO INC | [IMA](https://holderbook.com/stocks/IMA/) | $5.4M | 909,269 | 0.1% | 4 |
| ALNYLAM PHARMACEUTICALS INC | [ALNY](https://holderbook.com/stocks/ALNY/) | $5.1M | 17,000 | 0.1% | 9 |
| PALISADE BIO INC | [PALI](https://holderbook.com/stocks/PALI/) | $4.9M | 2,333,000 | 0.1% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +18.1% | +14.8% | +3.2% | 108% |
| Q1 2026 | +0.4% | -4.6% | +5.1% | 97% |
| Q4 2025 | +27.5% | +2.4% | +25.1% | 97% |
| Q3 2025 | +14.1% | +7.8% | +6.3% | 99% |
| Q2 2025 | +3.0% | +10.5% | -7.4% | 91% |
| Q1 2025 | -12.3% | -4.6% | -7.8% | 92% |
| Q4 2024 | -11.9% | +2.1% | -14.1% | 93% |
| Q3 2024 | +10.6% | +5.4% | +5.1% | 99% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $5.4B | 123 |
| Q1 2026 | $5.0B | 109 |
| Q4 2025 | $4.9B | 104 |
| Q3 2025 | $4.2B | 103 |
| Q2 2025 | $4.0B | 98 |
| Q1 2025 | $4.2B | 106 |
| Q4 2024 | $4.8B | 111 |
| Q3 2024 | $5.5B | 112 |
| Q2 2024 | $5.0B | 109 |
| Q1 2024 | $5.4B | 111 |
| Q4 2023 | $5.0B | 109 |
| Q3 2023 | $4.7B | 121 |